Clinical Trial Update: Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial update showing Evenamide as an add-on to standard of care for schizophrenia in people with treatment-resistant schizophrenia; currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Evenamide (Evenamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Treatment-resistant Schizophrenia | Phase 3 | Status: RECRUITING